SBP Group's TQ-A3334 TLR7 Agonist Unveils Phase II Clinical Data at 2026 AASLD

Stock News11-09

SBP Group (01177) has issued an announcement regarding its subsidiary.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), an affiliate of the group, has independently developed the national Class 1 innovative drug TQ-A3334, a TLR7 agonist, which was presented at the Late-Breaking Abstract Parallel Session of the 2026 American Association for the Study of Liver Diseases (AASLD) Annual Meeting.

The Phase II clinical study results were disclosed through an oral presentation.

TQ-A3334 is a novel, highly selective oral Toll-like receptor 7 (TLR7) agonist.

TLR agonists are capable of restoring depleted innate and adaptive immunity, thereby enhancing antiviral defense.

TQ-A3334 has previously demonstrated favorable safety and preliminary anti-hepatitis B virus (HBV) activity in prior clinical studies.

This Phase II study was designed to evaluate the efficacy and safety of TQ-A3334 in combination with nucleos(t)ide analogues (NAs) for the treatment of patients with chronic HBV infection.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment